Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients

Date
2016
Author
Tabak, F.
Sonneveld, M. J.
de Knegt, R. J.
Boonstra, A.
Hansen, B. E.
Janssen, H. L. A.
van Campenhout, M. J. H.
Brouwer, W. P.
van Oord, G. W.
Xie, Q.
Zhang, Q.
Zhang, N.
Guo, S.
Streinu-Cercel, A.
Wang, J.
Pas, S. D.
Metadata
Show full item record
Abstract
Hepatitis B core-related antigen (HBcrAg), a new serum marker, may be useful in monitoring chronic hepatitis B infection. HBcrAg was measured in 175 hepatitis B e antigen-positive patients treated with entecavir (ETV) with or without peginterferon (PEG-IFN) add-on therapy. Decline in HBcrAg was stronger in patients with vs. without combined response (ETV: -3.22 vs. -1.71 log U/mL, p <0.001; PEG-IFN add-on: -3.16 vs. -1.83 IU/mL, p <0.001) and in patients with vs. without hepatitis B surface antigen (HBsAg) response (ETV: -2.60 vs. -1.74 log U/mL, p <0.001; PEG-IFN addon: -2.38 vs. -2.15 log U/mL, p = 0.31). HBcrAg was associated with combined response (adjusted odds ratio 0.3, 95% confidence interval 0.2-0.5, p <0.001), but was not superior to quantitative HBsAg (qHBsAg). (C) 2016 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
URI
http://hdl.handle.net/20.500.12627/66269
https://doi.org/10.1016/j.cmi.2016.02.002
Collections